Elixinol Global Stock Performance
| ELLXF Stock | USD 0 0.0009 39.13% |
Elixinol Global holds a performance score of 9 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -29.5, which means a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Elixinol Global are expected to decrease by larger amounts. On the other hand, during market turmoil, Elixinol Global is expected to outperform it. Use Elixinol Global total risk alpha and the relationship between the potential upside and day typical price , to analyze future returns on Elixinol Global.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Elixinol Global are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite nearly unsteady basic indicators, Elixinol Global reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 27.7 M | |
| Total Cashflows From Investing Activities | 172 K |
Elixinol |
Elixinol Global Relative Risk vs. Return Landscape
If you would invest 0.15 in Elixinol Global on August 28, 2024 and sell it today you would earn a total of 0.17 from holding Elixinol Global or generate 113.33% return on investment over 90 days. Elixinol Global is currently producing 12.6858% returns and takes up 101.7512% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Elixinol, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Elixinol Global Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Elixinol Global's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Elixinol Global, and traders can use it to determine the average amount a Elixinol Global's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1247
| Best Portfolio | Best Equity | ELLXF | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 101.75 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Elixinol Global is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Elixinol Global by adding it to a well-diversified portfolio.
Elixinol Global Fundamentals Growth
Elixinol Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Elixinol Global, and Elixinol Global fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Elixinol Pink Sheet performance.
| Return On Equity | -0.71 | |||
| Return On Asset | -0.33 | |||
| Profit Margin | (1.72) % | |||
| Operating Margin | (1.63) % | |||
| Current Valuation | 2.06 M | |||
| Shares Outstanding | 316.27 M | |||
| Price To Book | 0.72 X | |||
| Price To Sales | 0.59 X | |||
| Revenue | 14.13 M | |||
| EBITDA | (24.15 M) | |||
| Cash And Equivalents | 6.93 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 250 K | |||
| Debt To Equity | 0.17 % | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (14.07 M) | |||
| Earnings Per Share | (0.04) X | |||
| Total Asset | 25.33 M | |||
About Elixinol Global Performance
By analyzing Elixinol Global's fundamental ratios, stakeholders can gain valuable insights into Elixinol Global's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Elixinol Global has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Elixinol Global has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Elixinol Wellness Limited, through its subsidiaries, manufactures and distributes hemp derived nutraceuticals, cosmetics, and food products under the Elixinol and Hemp Foods Australia brands in the Americas, Europe, and Australia. The company was incorporated in 2017 and is headquartered in Sydney, Australia. Elixinol Wellness operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.Things to note about Elixinol Global performance evaluation
Checking the ongoing alerts about Elixinol Global for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Elixinol Global help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Elixinol Global is way too risky over 90 days horizon | |
| Elixinol Global has some characteristics of a very speculative penny stock | |
| Elixinol Global appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 14.13 M. Net Loss for the year was (17.02 M) with profit before overhead, payroll, taxes, and interest of 4.9 M. | |
| Elixinol Global has accumulated about 6.93 M in cash with (14.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 16.0% of the company shares are held by company insiders |
- Analyzing Elixinol Global's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Elixinol Global's stock is overvalued or undervalued compared to its peers.
- Examining Elixinol Global's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Elixinol Global's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Elixinol Global's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Elixinol Global's pink sheet. These opinions can provide insight into Elixinol Global's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Elixinol Pink Sheet analysis
When running Elixinol Global's price analysis, check to measure Elixinol Global's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elixinol Global is operating at the current time. Most of Elixinol Global's value examination focuses on studying past and present price action to predict the probability of Elixinol Global's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elixinol Global's price. Additionally, you may evaluate how the addition of Elixinol Global to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |